Clinical Trials Logo

Clinical Trial Summary

Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory. This medicine has been used in the past to treat pain. But, in this study, it will be used to prevent new brain metastasis. This is the first time that meclofenamate will be used in patients with brain metastasis. This is a pilot study which means that the purpose of this study is to determine if a larger clinical trial of meclofenamate is possible in patients with brain metastasis. This study also aims to find out what effects, good and/or bad meclofenamate has on the patient and the cancer that has spread to the brain. The investigators also want to learn more about potential effects that this drug may have in the digestive system.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02429570
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Active, not recruiting
Phase N/A
Start date April 22, 2015
Completion date April 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04690348 - Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study Phase 2
Terminated NCT02166658 - A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) Phase 2